Roivant Sciences(ROIV) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, November 12, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. • Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-inindication efficacy sustained to one year; first patients enrolled ...